Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Key Highlights
- ➤MRT-8102 GFORCE-1 Phase 1 results presentation scheduled for October 1, 2026
- ➤Safety and activity data will cover multiple MRT-8102 dose levels after 4 weeks
- ➤MRT-8102 data will show modulation of multiple ASCVD pathogenic drivers
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) by MRT-8102.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.
Get started
Create a free account to read the full story.